Abbott Receives FDA Approval for the Liberta RC™ DBS System

Abbott has received the US FDA approval for the Liberta RC™ DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people living with movement disorders.

The Liberta RC DBS system is the only rechargeable DBS device compatible with Abbott’s proprietary NeuroSphere™ Virtual Clinic, a first-of-its-kind connected care technology in the U.S. that allows people to communicate with their doctors, ensure proper settings and functionality, and receive new treatment settings remotely as needed without stepping foot in a doctor’s office. Abbott developed NeuroSphere Virtual Clinic after research showed that the average Abbott DBS user in the U.S. must travel more than 150 miles to access a movement disorder specialist.

The Liberta RC DBS system is about 31% smaller than other commonly used implantable, rechargeable DBS devices currently available in the U.S. When used under standard settings, it needs to be recharged as few as every 37 days – or 10 times a year – using a wireless charger that is placed over the device. The system, which can be controlled on an Abbott supplied patient controller or a compatible and secure iOS device, offers users helpful notifications and customizable settings for a personalized charging experience.

To view the source version, please click HERE.

en_GBEnglish (UK)